AZ's lesinurad misses in Phase III gout at lower dose

AstraZeneca's gout treatment lesinurad used in combination with Takeda Pharmaceutical's Uloric (febuxostat), has missed its primary endpoint at the lower 200mg dose tested in another Phase III trial.